A B S T R A C T The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 ug were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 gg were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.
INTRODUCTION
Infections caused by Pseudomonas aeruginosa have been particularly difficult to treat due to the organism's resistance to many antibiotics, the severity of the hosts' underlying condition that predisposes to P. aeruginosa infection, and the rapidity with which a septicemia can be fatal (1, 2) . Immunotherapeutic modalities have been proposed as a potential means of increasing host resistance to this organism. Antibody directed towards cell surface lipopolysaccharide (LPS)' determinants has been shown to be effective in mediating opsonophagocytic killing of P. aeruginosa (3, 4) . This antibody has been detected in the serum of patients convalescing from P. aeruginosa sepsis (5, 6) , and survival of a P. aeruginosa sepsis episode has been associated with high levels of antibody to LPS in the acute phase serum (7) . Attempts to induce antibody to LPS determinants in burn patients (8) , cancer patients (9) , and children with cystic fibrosis (10) have been hampered by the toxicity of LPS when used as a human vaccine. Nonetheless, these studies did suggest a drop in P. aeruginosa associated mortality following the use of an LPS vaccine. Recently, Jones et al. (11) documented the efficacy of a P. aeruginosa vaccine plus immunoglobulin in burn patients. Although the serologically active component of this vaccine has yet to be identified, the method of preparation (12) suggests it may be LPS.
A safe and immunogenic vaccine containing P. aeruginosa LPS serotype determinants would thus appear to be an ideal candidate for an immunotherapeutic agent to prevent P. aeruginosa sepsis. High molecular weight polysaccharide (PS) isolated from the supernate of P. aeruginosa cultures has been shown to be immunogenic in animals (13), to elicit protection to live organism challenge (14, 15) and to be nontoxic in mice and guinea pigs and nonpyrogenic in rabbits (14, 15) . These PS antigens share serological specificity with the "O" specific side chain of LPS, yet differ from "O" side chains by their immunogenicity, biochemical constituents, monosaccharide composition, and molecular size (14, 15 Subjects. 42 normal healthy adult volunteers were asked to participate in this study. Signed informed consent was obtained, the volunteers randomly assigned to one of four groups receiving various doses of the vaccine, 20 ml of blood obtained by venipuncture, then a 0.5-ml subcutaneous injection of the vaccine given in the deltoid region of the arm. Subjects were interviewed at 24 and 48 h after the injection, symptoms noted, and temperatures recorded. Postimmunization sera were obtained at 14-and 28-d intervals following injection. For some subjects, serum was also obtained 6 mo postinjection.
Serologic methods. Serum antibody levels to the IT-1 PS were quantitated by means of a radioactive antigen binding assay using intrinsically labeled [14C]PS prepared as previously described (13, 16) . Sera were separated and stored at -20°C. Quantitation was performed as previously described for animal sera (16) Opsonophagocytosis assays were performed by an adaptation of the methods of Baltimore et al. (17) and Young (4) . Human peripheral blood leukocytes were purified on a dextran gradient, freed of erythrocytes, and suspended to 107 cells per milliliter. P. aeruginosa IT-1 was harvested in mid-log growth phase, washed once with minimal essential media (Microbiological Associates, Bethesda, Md.) and resuspended to 3 X 107 organisms/ml. The reaction mixture consisted of 100 ul of the serum or serum dilution to be tested, 100 Ml of cells, 100 Ml of organisms, and 100 Ml of a 1:5 dilution of guinea pig complement. A 25-Ml aliquot was removed from the tube at time 0, diluted in distilled water to lyse the leukocytes, then further diluted in saline and plated out on trypticase soy agar plates for bacterial enumeration. A similar aliquot was removed following 60 min of incubation at 37°C where tubes were continuously mixed, and organisms counted. The opsonic titer of the serum was expressed as the reciprocal of the serum dilution killing 90% or more of the initial inoculum. Controls for each experiment included mixtures of two of three components (cells, serum, and complement) plus organisms and media.
Statistical methods. Differences in the concentration of antibody in preimmunization and postimmunization sera were compared by a t test (18) . Antibody titer rises of fourfold or greater in the opsonophagocytic assay were considered a positive response and analysis of responses between groups receiving different doses were compared by logistic regression (19) .
RESULTS
Chemical analyses. The results of analyses for the various biochemical and monosaccharide constituents of the IT-1 high molecular weight PS are shown in 250 Mg had these responses. In the total population, 32 persons had preimmunization titers of two or less, 8 had preimmunization titers of four through eight and 2 had preimmunization titers of more than eight. After immunization, 7 persons had titers of 2 or less, 13 had titers of [4] [5] [6] [7] [8] and 23 had titers of 1:16 or greater, up to 1:128. Logistic regression analyses of the dose response effect was performed on these data. Responses were designated 1 or 0 to indicate whether or not a fourfold or greater titer rise had occurred. The responses at 50 and 75 Mg were treated as one category (low dose) for these statistical purposes. A highly significant difference (P < 0.001) was observed between the response seen in the group immunized with 150 and 250,Mg, when compared to the response of the 50-and 75-i,g group. The difference in response between 150-and 250-,gg doses was marginally significant, (P = 0.079). This suggested a trend for the higher dose being slightly more efficacious in inducing a functional antibody response. DISCUSSION Disease due to P. aeruginosa infections is most often seen in immunocompromised or traumatized hosts. Susceptibility to infection has been thought to be correlated with granulocytopenia (2), though the underlying host condition was found to be a better indicator of the severity and outcome of P. aeruginosa sepsis (20) . These immunocompromised patients, who are at risk for developing P. aeruginosa infections, are altered in their responses to immunological stimuli, and therefore may not respond to the PS antigen with humoral antibody, as was shown here for normal volunteers. Vaccination of granulocytopenic populations generally results in poor immune responses, but there are certain populations who are at high risk for P. aeruginosa infections that can be immunized prophylactically. Other populations, such as burn and trauma victims, may respond adequately to vaccination if given soon enough after injury. Immunosuppressed populations can potentially be immunized before or in between courses of therapy. Since the PS vaccine used here induced both binding and opsonic antibody, and has minimal toxicity in vaccinees, it offers the possibility to function as an effective immunotherapeutic agent for preventing P. aeruginosa sepsis. PS antigens are prepared by a method utilizing heat and acid to cleave the contaminating LPS into its lipid A, "O" side chain and core components for subsequent elimination. This somewhat harsh method was chosen because it was found to be the only method that removed all detectable intact LPS. Although low levels of LPS contamination in a vaccine may not be of any concern if the toxicity is within acceptable limits, animal studies of numerous P. aeruginosa vaccines have often indicated that contaminating LPS is the responsible agent for the immunogenicity and protective efficacy seen (14) . The immunogenicity of this PS vaccine in humans, coupled with its almost total lack of toxicity, indicates that the acetic acid method for elimination of LPS is not only an effective procedure for reducing toxicity, but does not interfere with immunogenicity.
The magnitude of the human immune response to PS is particularly good when compared to the amount of antibody inducible in experimental animals (16) . Humans by far had a greater degree of response than we have found for the most responsive laboratory animal, the C3H mouse strain. The opsonic titers we obtained in our vaccinees was also close to that reported by Young and Armstrong (3) and Young (4) for patients recovering from P. aeruginosa sepsis or immunized with an LPS vaccine. The opsonophagocytosis test they used was very similar to the one used here, except that they multiplied their titers by a factor of 10 to translate the 0.1-ml amount of serum used in the reaction mixture to 1.0 ml. The data here report the dilution of a 0.1-ml amount of serum that elicited killing. Another slight difference was their use of 270% reduction in viable organisms as representing killing, while we used .90% levels. Taking this into account, the phagocytic titers of 12 persons recuperating from P. aeruginosa bacteremia ranged from 32 to 2,048 (our method), with 8 of these patients (66.7%) having titers of 32-128. 12 The influence of antibody levels of P. aeruginosa LPS serotype determinants in affecting the outcome of P. aeruginosa infection has been suggested by both vaccine studies (8, 9, 11) and also by a study of the influence on survival of acute phase antibody levels to LPS (7) . Our studies in animals, (14, 15) 
